| Pratima M Mehta, MD | |
|
5825 Broadway, Suite A, Merrillville, IN 46410-2687 | |
| (219) 884-1400 | |
| (219) 884-1453 |
| Full Name | Pratima M Mehta |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 5825 Broadway, Merrillville, Indiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780693341 | NPI | - | NPPES |
| 247800C | Other | IN | GROUP INDIVIDUAL |
| 247800 | Other | IN | GROUP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01032516A (Indiana) | Primary |
| 146D00000X | Personal Emergency Response Attendant | 01032516A (Indiana) | Secondary |
| Entity Name | Edgewater Systems For Balanced Living Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588705784 PECOS PAC ID: 9234398397 Enrollment ID: O20120308000405 |
News Archive
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
Gender-based violence could be tackled more effectively by giving healthcare students wider and more practical education and training in identifying and responding to the 'warning signs' presented among patients they will encounter in professional life, according to a new study.
Bristol-Myers Squibb today announced the launch of Daklinza▼ (daclatasvir) in the UK, a new medicine for the treatment of adult patients with chronic hepatitis C. Daclatasvir, a treatment that works across multiple hepatitis C genotypes, will allow up to 90% of UK patients the option of a potentially curative oral treatment regimen that does not include interferon, a standard of care commonly associated with sustained flu-like side effects.
The chairs of the Consultative Expert Working Group on Research and Development (CEWG), John-Arne Rottingen and Claudia Chamas, in this week's PLoS Medicine, "recommended the May 2012 World Health Assembly adopt an international convention on research and development (R&D) that will bind member states to action and catalyze new knowledge for diseases that primarily affect the global poor but for which patents provide insufficient market incentives," a PLoS press release states.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pratima M Mehta, MD 441,scarborough Road,, Valparaiso, IN 46385-8008 Ph: (219) 465-1834 | Pratima M Mehta, MD 5825 Broadway, Suite A, Merrillville, IN 46410-2687 Ph: (219) 884-1400 |
News Archive
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
Gender-based violence could be tackled more effectively by giving healthcare students wider and more practical education and training in identifying and responding to the 'warning signs' presented among patients they will encounter in professional life, according to a new study.
Bristol-Myers Squibb today announced the launch of Daklinza▼ (daclatasvir) in the UK, a new medicine for the treatment of adult patients with chronic hepatitis C. Daclatasvir, a treatment that works across multiple hepatitis C genotypes, will allow up to 90% of UK patients the option of a potentially curative oral treatment regimen that does not include interferon, a standard of care commonly associated with sustained flu-like side effects.
The chairs of the Consultative Expert Working Group on Research and Development (CEWG), John-Arne Rottingen and Claudia Chamas, in this week's PLoS Medicine, "recommended the May 2012 World Health Assembly adopt an international convention on research and development (R&D) that will bind member states to action and catalyze new knowledge for diseases that primarily affect the global poor but for which patents provide insufficient market incentives," a PLoS press release states.
› Verified 8 days ago
Johann David Farley, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8300 Broadway Ste D2, Merrillville, IN 46410 Phone: 219-649-0044 Fax: 219-649-0055 | |
Dr. Brian H Weiss, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 300 West 80th Ave., Ste A, Merrillville, IN 46410 Phone: 219-791-9785 Fax: 219-791-9787 | |
Dr. Oranu G Ibekie, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 1574 E 85th Ave, Merrillville, IN 46410 Phone: 219-769-4400 Fax: 219-795-1419 | |
Dr. Syed S Kazmi, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 616 W 81st Ave, Merrillville, IN 46410 Phone: 312-421-1016 | |
Fadi I Alzeidan, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 7863 Broadway, Merrillville, IN 46410 Phone: 219-769-6639 Fax: 219-769-0636 | |
Jessica Jean Glinski, DNP, FNP-BC Family Medicine Medicare: Medicare Enrolled Practice Location: 5043 E 81st Ave, Merrillville, IN 46410 Phone: 219-707-5276 | |
Lauren Dandurand, AGACNP-BC Family Medicine Medicare: Medicare Enrolled Practice Location: 200 E 89th Ave Ste 2a, Merrillville, IN 46410 Phone: 219-736-2800 |